- Recognized for its safety and potential following an assessment by the National Evidence-based Healthcare Collaborating Agency (NECA)
- DEEP:NEURO, the brain image detection and diagnostic assistance software for cerebral aneurysms developed by DEEPNOID, one of Korea’s first-generation medical AI companies, has been designated as an Innovative Medical Technology.
In March 2023, DEEP:NEURO was designated as an Innovative Medical Device through the integrated review for innovative medical devices conducted by Korea’s Ministry of Food and Drug Safety (MFDS) and related government agencies. The review recognized the product’s technological innovation and market potential, and following a final assessment by the National Evidence-based Healthcare Collaborating Agency (NECA), DEEP:NEURO was designated as an Innovative Medical Technology on August 14, 2023. With this designation, DEEPNOID can now bring DEEP:NEURO to the clinical market under temporary non-reimbursable status.
DEEP:NEURO uses AI to interpret and analyze brain magnetic resonance angiography (MRA) images of patients with suspected cerebral aneurysms, identifying suspected aneurysm regions to support clinicians’ diagnosis. When reviewing cerebral aneurysm findings on brain MRA, clinicians can use DEEP:NEURO in clinical settings as an interpretation support tool. By improving the convenience and accuracy of image interpretation, DEEP:NEURO is expected to help clinicians respond quickly and protect the critical treatment window for cerebrovascular diseases that require prompt care.
“Following its designation as an Innovative Medical Device in March, DEEP:NEURO’s designation as an Innovative Medical Technology is a significant achievement that recognizes DEEPNOID’s medical AI technology and expertise,” said Woosik Choi, CEO of DEEPNOID. “We hope DEEP:NEURO will help protect the critical treatment window for cerebrovascular diseases, particularly cerebral aneurysms, and contribute to public health.”
DEEPNOID plans to enter Southeast Asian markets starting in the second half of 2023, while preparing for expansion into the United States and Europe, with the goal of generating overseas revenue in 2024. “We are accelerating our preparations to enter Southeast Asia, including Vietnam, and expect to see tangible results starting next year,” Choi said.
###
